Home›Companies›Biotech & Pharma›Ultivue

Ultivue, Inc.

Updated Oct 27, 2026·Latest SEC filing Jul 25, 2024·Suggest an edit

About Ultivue

Ultivue is a private company based in Cambridge, Massachusetts. It has reported $55,227,259 raised in four offerings on Form D since August 2015.

Funding Rounds (SEC Form D)

First saleFiled with SECAmount soldInvestorsAvg. checkTermsFiling
Jul 11, 2024Jul 25, 2024$3,324,270of $14.9M target5$664KEquityRule 506(b)Form D ↗
Jun 13, 2019Jun 28, 2019$26,502,993fully sold14$1.8MEquityRule 506(b)Form D ↗
Jul 6, 2017Jul 21, 2017amended Feb 1, 2018$20,249,996of $20.4M target11$1.8MEquityRule 506(b)Form D/A ↗1 earlier filing
Aug 7, 2015Aug 21, 2015$5,150,000fully sold6$858KEquityRule 506(b)Form D ↗
Total, four offerings$55,227,259

First sale is the date the first investor in the offering committed to invest. Companies must file Form D within 15 days of that date, so filing dates run later.

Leadership Team

Executive officers and directors listed on Ultivue's Form D filed Jul 25, 2024.

AJ
Andrea Jackson
Director
Also a director at Vizgen.
KC
Keith Crandell
Director
Also a director at Vizgen.
PY
Peng Yin
Director
Fenel Eloi
Fenel Eloi
Director
Also a director at Mitotherapeutix and VIC Technology Venture Development and a managing partner, P&M capital partners, director at Terrestrial.
RC
Robert Carson
President and director
Also a president and CEO, director at Vizgen.

Earlier filings also listed Wen Chen (director, last listed Jun 2019), Sharon Kedar (director, last listed Jun 2019), Michael Natan (president and director, last listed Jun 2019), Lian Chen (director, last listed Jun 2019), David Walt (director, last listed Jun 2019), Andrew Stevenson (director, last listed Jun 2019), Peng Ying (executive officer and director, last listed Aug 2015) and David Walt (president and director, last listed Aug 2015).

Sources

  1. SECUltivue, Inc. Form D, filed Jul 21, 2017
  2. SECUltivue, Inc. filing history